Yes I liked the presentation also. Key driver of PPS ( besides DME deal ) will be the FDA lifting their partial hold on their P3 RZ358 program This will allow some US patients to be enrolled in the trial ...read out mid 2025 ...and make it easier for US approval assuming trial succeeds .
RZ358 for cancer patients with hyperglycemia looks interesting also ...sounds as tho they will proceed with that .
RZ358 P2 patients are apparently still on the drug under expanded use and now they have 2 yrs of data on them .
RZ402 ...their DME drug. His comments ...Exciting data , more detail at conferences , lots of interest ( from BP ) that they will explore or are exploring .
General notes ...patent protection to 2035 , 2036 and cash out to Q3 2025 ( so expect a capital raise at some pt unless they sell the DME indication for huge $ )
Kiwi
PS. chk the vol in UNCY ...huge churn , PPS going no where as I type
News 
Market Data 
Discover 
